Project Grant R41AI194849
Award Date 8/21/25
Completion Date 7/31/27
Dollars Obligated $299K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
East Lansing, MI 48823, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2,248,740 Project Grant through the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to Michigan State University on July 7, 2025. The grant supports the development of a new series of nitrofuran compounds that are potent inhibitors against Mycobacterium tuberculosis (MTB) and Mycobacterium abscessus (MAB), the bacteria that cause tuberculosis and non-tuberculous mycobacterial infections,...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $429,546 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to National Jewish Health in Colorado. The grant will fund research to evaluate the efficacy of tuberculosis (TB) treatment regimens by analyzing the transcriptomic patterns of Mycobacterium tuberculosis injury and adaptation during drug treatment. The research aims to develop more reliable preclinical measures of TB treatment...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $301,826 Project Grant on August 20, 2025 to the University of Washington to develop novel agents to eliminate tuberculosis (TB) persisters. The grant, under CFDA 93.855 - Allergy and Infectious Diseases Research, aims to assess the potential of the FDA-approved drug netupitant (NTP) as an anti-persister agent for TB treatment. The University of Washington will use molecular genetic and biochemical strategies to define...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $300,000 in funding to Fimbrion Therapeutics Inc. in Missouri to develop an orally bioavailable thiazolino-pyridone (TZP) small molecule series with inhibitory activity against Mycobacterium tuberculosis. The goal is to create a first-in-class TZP compound that could become a novel drug for treating...
- This $193,375 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify bacterial determinants that may contribute to variable treatment responses for tuberculosis (TB). The project, conducted by researchers at the Harvard T.H. Chan School of Public Health, aims to investigate the effects of clinically prevalent variants in the ESX1 secretion system on TB...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $536,148 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Tufts University School of Medicine to conduct research on integrating point-of-care urine isoniazid testing into routine tuberculosis (TB) care in India. The research aims to facilitate early and accurate identification of TB patients who are at risk of poor outcomes, including death and disease recurrence, due to...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $750,000 Project Grant to The University of Southern Mississippi to research the role of extracellular polyphosphate in Mycobacterium tuberculosis antibiotic tolerance. The 4-year grant, which begins on Sep 20, 2025 and runs through Aug 31, 2029, aims to investigate the metabolic pathways in M. tuberculosis that regulate extracellular...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2,922,220 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Johns Hopkins University. The grant supports research to advance apoptosis-inducing agents as host-directed therapy for tuberculosis (TB). The research aims to boost host immune responses via the intrinsic apoptosis pathway to reduce Mycobacterium tuberculosis (MTB) growth and enhance the bactericidal activity of...
- This federal Project Grant award of $300,001 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research by Fimbrion Therapeutics Inc. to develop novel small molecule drugs targeting the respiratory protein QcrB in mycobacteria. The goal is to create new antimicrobial therapies to treat infections caused by non-tuberculous mycobacteria (NTM), which are highly resistant to existing antibiotics...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $721,194 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Florida State University (FSU) to conduct research on membrane protein complexes involved in the cell division process of Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis (TB). The 5-year project, beginning March 1, 2025, aims to structurally characterize the FtsQ-FtsZ and FtsQ-FtsB-FtsL protein...